Maurizio Zangari
Professor
Also affiliated: University of Maryland, Baltimore (2003); Mount Sinai Hospital (2013); Hackensack University Medical Center (2003); The University of Texas MD Anderson Cancer Center (2009); Harvard University (2003); National and Kapodistrian University of Athens (2009); Medical College of Wisconsin (2003); Cornell University (2009); University of Utah (2008–2019); University of Arkansas Medical Center (2003–2026); Huntsman Cancer Institute (2009–2019); Universitätsklinikum Erlangen (2003); Fred Hutch Cancer Center (2000–2002); Central Arkansas Veterans Healthcare System (2001–2002); Cancer Research And Biostatistics (2003–2008); Dana-Farber Cancer Institute (2003); Dana-Farber/Harvard Cancer Center (2003); National Cancer Institute (2002); Ospedale San Bortolo (2009); Celgene (United States) (2009); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (2003); Icahn School of Medicine at Mount Sinai (1995–1999)
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Maurizio Zangari, M.D. is a Professor of Medicine at the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute for Research and Therapy. His research focuses on multiple myeloma, investigating its molecular underpinnings, evolutionary pathways, and the impact of therapeutic interventions. Dr. Zangari has published extensively on topics including the molecular characteristics of smoldering myeloma, the spatio-temporal evolution of the disease, and the role of the immune microenvironment in its progression.
His work also addresses critical aspects of treatment, such as the risk of infections associated with novel therapies like bispecific antibodies, and the changing spectrum of infections in patients undergoing treatment with BCMA and GPRC5D targeting bispecific antibodies. Dr. Zangari has also examined disparities in access to advanced therapies, including CAR T-cells and bispecific antibodies, for multiple myeloma, and contributed to research on the enrollment of Black participants in pivotal clinical trials for hematological malignancies. He holds a highly cited researcher designation, with a significant publication and citation record.
Dr. Zangari's academic background includes fellowship training in Bone Marrow Transplant and Hematology at Mount Sinai Hospital and residency in Internal Medicine at Wykoff Heights Medical Center, both in New York. He earned his M.D. from the University of Padua, Italy. He is board certified in Hematology and Internal Medicine and is a member of the American Society of Hematology. He leads a research group and collaborates with several colleagues at UAMS.
Research Overview
Maurizio Zangari, M.D. is a Professor of Medicine with the Myeloma Institute for Research and Therapy at UAMS. Dr. Zangari trained as a fellow in Bone Marrow Transplant and Hematology at Mount Sinai Hospital in New York and a resident in Internal Medicine at Wykoff Heights Medical Center, also in New York. He earned is MD from the University of Padua in Italy. Dr. Zangari was previously at the Myeloma Center from 1998-2007, then left for the University of Utah from 2007-2013. He rejoined the Myeloma Center in 2013 and continues to be greatly involved with clinical trials and research. He is an internationally recognized expert in multiple myeloma with an extensive bibliography of peer-reviewed articles and invited presentations. Dr. Zangari is board certified in Hematology and Internal Medicine. He is a member of the American Society of Hematology.
Metrics
- h-index: 71
- Publications: 530
- Citations: 19,736
Positions
-
Professor publications 2000–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
MM-224: Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma (2026)
-
MM-226: Safety and Effectiveness of Bispecific Antibody Therapy Across the Spectrum of Kidney Function in Relapsed/Refractory Multiple Myeloma (2026)
-
POSTER: MM-224: Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma (2026)
-
POSTER: MM-226: Safety and Effectiveness of Bispecific Antibody Therapy Across the Spectrum of Kidney Function in Relapsed/Refractory Multiple Myeloma (2026)
-
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)
-
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
-
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
Research Interests
Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.
Grants & Funding
As listed on this researcher's institutional profile.
- 2005-02 (The CAFÉ Study): CAncer-related Fracture Evaluation - A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty Kyphon, Inc Principal Investigator
- UARK 2002-09 Protocol F7SCT-1485, A Multicenter, Randomized, Double Blind, Parallel Groups, Placebo Controlled Trial on Efficacy and Safety of Activat Novo Nordisk Principal Investigator
- MLN 9708 Millennium Pharmaceuticals, Inc. Principal Investigator
- UARK 2002-37, An Open Label Phase II Extension Study to Assess the Long-Term Safety and Tolerability of MRA Given to Patients with Multiple Myeloma Chugai Biopharmaceuticals, Inc. Principal Investigator
Collaboration Network
Top Collaborators
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Showing 5 of 118 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
Showing 5 of 93 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 84 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Showing 5 of 78 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 77 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Showing 5 of 42 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Showing 5 of 40 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Showing 5 of 38 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Showing 5 of 37 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 33 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 32 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Inhibiting MEK in MAPK pathway-activated myeloma
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
Showing 5 of 26 shared publications
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Results of autologous stem cell transplant in multiple myeloma patients with renal failure
- Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
- Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
Showing 5 of 26 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Treatment of multiple myeloma
Showing 5 of 26 shared publications
- The molecular classification of multiple myeloma
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Showing 5 of 25 shared publications
Similar Researchers
Based on overlapping research topics